JP2020531530A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531530A5
JP2020531530A5 JP2020511364A JP2020511364A JP2020531530A5 JP 2020531530 A5 JP2020531530 A5 JP 2020531530A5 JP 2020511364 A JP2020511364 A JP 2020511364A JP 2020511364 A JP2020511364 A JP 2020511364A JP 2020531530 A5 JP2020531530 A5 JP 2020531530A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
salt
composition according
item
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511364A
Other languages
English (en)
Japanese (ja)
Other versions
JP7386536B2 (ja
JP2020531530A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/047323 external-priority patent/WO2019040491A1/en
Publication of JP2020531530A publication Critical patent/JP2020531530A/ja
Publication of JP2020531530A5 publication Critical patent/JP2020531530A5/ja
Priority to JP2023121658A priority Critical patent/JP2023129623A/ja
Application granted granted Critical
Publication of JP7386536B2 publication Critical patent/JP7386536B2/ja
Priority to JP2025083816A priority patent/JP2025131620A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511364A 2017-08-22 2018-08-21 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用 Active JP7386536B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023121658A JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
JP2025083816A JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548848P 2017-08-22 2017-08-22
US62/548,848 2017-08-22
PCT/US2018/047323 WO2019040491A1 (en) 2017-08-22 2018-08-21 MODIFIED ALKYL CHAIN IMIDAZOQUINOLINE TLR7 / 8 AGONIST COMPOUNDS AND USES THEREOF

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023121658A Division JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2020531530A JP2020531530A (ja) 2020-11-05
JP2020531530A5 true JP2020531530A5 (cg-RX-API-DMAC7.html) 2021-09-16
JP7386536B2 JP7386536B2 (ja) 2023-11-27

Family

ID=63638354

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020511364A Active JP7386536B2 (ja) 2017-08-22 2018-08-21 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
JP2023121658A Pending JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
JP2025083816A Pending JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023121658A Pending JP2023129623A (ja) 2017-08-22 2023-07-26 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用
JP2025083816A Pending JP2025131620A (ja) 2017-08-22 2025-05-20 アルキル鎖修飾イミダゾキノリンtlr7/8アゴニスト化合物およびその使用

Country Status (5)

Country Link
US (4) US10618896B2 (cg-RX-API-DMAC7.html)
EP (2) EP4257198A3 (cg-RX-API-DMAC7.html)
JP (3) JP7386536B2 (cg-RX-API-DMAC7.html)
ES (1) ES2951817T3 (cg-RX-API-DMAC7.html)
WO (1) WO2019040491A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4257198A3 (en) * 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
BR112022008039A2 (pt) 2019-10-29 2022-07-12 Prime Reach Trading Ltd Compostos de 4-amino-imidazoquinolina e usos relacionados
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
EP4146204A4 (en) * 2020-05-05 2024-07-03 Virovax LLC Vaccine adjuvants
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
CN113967256B (zh) * 2021-10-26 2022-09-30 山东大学 一种具有光热-化疗-免疫功能的纳米粒及其制备方法和应用
US20250025447A1 (en) * 2021-11-03 2025-01-23 Regents Of The University Of Minnesota Toll-like receptor agonists and antagonists and uses thereof
WO2023086890A1 (en) * 2021-11-10 2023-05-19 The University Of Chicago Small molecule immunopotentiator conjugates of nfkb activators as adjuvants with enhanced efficacy and reduced toxicity
CN116731015B (zh) * 2023-05-18 2024-09-27 深圳威科森生物医药科技有限公司 咪唑并喹啉化合物及其制备方法、应用和组合物
EP4731632A1 (en) * 2023-06-21 2026-04-29 The Trustees of The University of Pennsylvania Toll-like receptor (tlr) agonist lipidoid compounds, lipid nanoparticles (lnps) comprising the same, and methods of use thereof
WO2025110816A1 (ko) 2023-11-23 2025-05-30 프로지니어 주식회사 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법
WO2026046400A1 (zh) * 2024-08-30 2026-03-05 惠正奇生物技术(广州)有限公司 含杂芳环结构的脂质类化合物及其应用
CN119320387B (zh) * 2024-12-19 2025-06-27 杭州天龙药业有限公司 基于Toll样受体激动剂的疫苗佐剂脂质化合物及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd 1−(置換アリール)アルキル−1h−イミダゾピリジン−4−アミン誘導体
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
HUP0201425A3 (en) 1999-04-23 2006-07-28 Hadasit Med Res Service Conjugate having a cleavable linkage for use in a liposome
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US6818650B2 (en) 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
JP2006513212A (ja) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー アリール/ヘタリール置換されたイミダゾキノリン
US7387271B2 (en) 2002-12-30 2008-06-17 3M Innovative Properties Company Immunostimulatory combinations
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
AU2004229478B2 (en) 2003-04-10 2009-12-24 3M Innovative Properties Company Delivery of immune response modifier compounds
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2535338C (en) 2003-08-14 2013-05-28 3M Innovative Properties Company Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
RU2006121646A (ru) 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
EP1765348B1 (en) 2004-06-18 2016-08-03 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co CONJUGATES TO MODIFY IMMUNE REACTIONS
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体(tlr)を介して作用するイミダゾキノリン
US8728486B2 (en) * 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9556167B2 (en) 2012-05-02 2017-01-31 Yale University TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs)
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
WO2014113634A1 (en) 2013-01-17 2014-07-24 University Of Kansas Toll-like receptor 2-agonistic lipopeptides, and method of making the same
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
US10471139B2 (en) 2013-08-15 2019-11-12 The University Of Kansas Toll-like receptor agonists
GB201321242D0 (en) 2013-12-02 2014-01-15 Immune Targeting Systems Its Ltd Immunogenic compound
EP3092256B1 (en) 2014-01-10 2022-05-18 Birdie Biopharmaceuticals Inc. Compounds and compositions for immunotherapy
SG11201608299TA (en) 2014-05-01 2016-11-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
WO2017044803A1 (en) 2015-09-09 2017-03-16 The United States Of America, As Represented By The Secretary Department Of Health And Human Service Expression vector delivery system and use thereof for inducing an immune response
EP3356371A4 (en) 2015-09-29 2020-06-24 The University of Chicago POLYMER CONJUGATE VACCINE
CR20180229A (es) 2015-10-29 2018-08-24 Novartis Ag Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
WO2018112108A1 (en) 2016-12-13 2018-06-21 Bolt Biotherapeutics, Inc. Antibody adjuvant conjugates
US10328895B2 (en) 2017-03-17 2019-06-25 Autoliv Asp, Inc. Seatbelt pretensioning retractor assembly including a pretensioner rod
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US20180311334A1 (en) 2017-04-29 2018-11-01 Yale University Compositions and Methods for Inducing an Immune Response
EP4257198A3 (en) 2017-08-22 2023-10-18 Dynavax Technologies Corporation Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
BR112020004505A2 (pt) 2017-09-06 2020-09-15 BioNTech SE imidazoquinolinas substituídas como agonistas de tlr7
US10722591B2 (en) 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof

Similar Documents

Publication Publication Date Title
US10993956B2 (en) GLA monotherapy for use in cancer treatment
JP6515182B2 (ja) Wt1抗原ペプチドおよび免疫調節剤の併用
US12186304B2 (en) Method for treating cancer by combination of IAP inhibitor and modulator of immune checkpoint molecule
JP2018508572A (ja) 免疫チェックポイント阻害薬と併用するプリナブリンの使用
RS59134B1 (sr) Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća
JP2017515802A5 (cg-RX-API-DMAC7.html)
EP3371210B1 (en) Combination therapy for malignant diseases
JP6240083B2 (ja) 樹状細胞癌ワクチンのための小分子エンハンサー
EP3672969A1 (en) Alkyl chain modified imidazoquinoline tlr7/8 agonist compounds and uses thereof
JP2015517511A5 (cg-RX-API-DMAC7.html)
CN112351795A (zh) 采用抗癌药剂和以包含非典型hla-i及新抗原复合物为靶点的抗体的联合抗癌疗法
JP2023539625A5 (cg-RX-API-DMAC7.html)
JP2022512384A5 (cg-RX-API-DMAC7.html)
CN111973747A (zh) 用于联合治疗卵巢癌的喹啉衍生物
EP3976193A1 (en) Dosing of bispecific t cell engager
KR20240006683A (ko) TLR8 조절 화합물과 항-HBV siRNA 치료제의 조합물
WO2017038997A1 (ja) Allergin-1アンタゴニストによるがん免疫増強剤
US20210353749A1 (en) Guanabenz as an adjuvant for immunotherapy
US12090202B2 (en) Combination of plasma immunoglobulin and antigen-specific immunoglobulin for the modification of the immune system and the treatment or prevention of allergic diseases
CN111328330A (zh) 作为免疫调节剂的磷铂化合物及其治疗用途
US20160022777A1 (en) Combination therapy with il-12
RU2026105366A (ru) Лечение рака легкого с помощью анти-pd-1 и химиотерапии
HK40015605A (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule